The recent Semaglutide Cardiovascular Outcomes Trial (SOUL) reported that once-daily oral semaglutide (maximal dose, 14 mg), in addition to standard care, significantly reduces the risk of MACE in individuals with type 2 diabetes and atherosclerotic cardiovascular disease, chronic kidney disease, or both, without an increase in the incidence of serious adverse events [6]
Its activity increases after stress in response to glucocorticoids and neuronal stimulation (Saito et al., 2001)
By activating both pathways simultaneously, tirzepatide produces significant improvements in glycaemic control and substantial weight reduction
Flavanones are distinguished by their action on the NO-cGMP signaling pathway, whereas isoflavones focus on the Keap1/Nrf2 axis
In Silico Pharmacol
PubMed laboratory research record [PMID: 41129057] PubMed record related to this compound for laboratory literature review